Literature DB >> 22841718

E-cadherin dysfunction in gastric cancer--cellular consequences, clinical applications and open questions.

Patrícia Carneiro1, Maria Sofia Fernandes, Joana Figueiredo, Joana Caldeira, Joana Carvalho, Hugo Pinheiro, Marina Leite, Soraia Melo, Patrícia Oliveira, Joana Simões-Correia, Maria José Oliveira, Fátima Carneiro, Céu Figueiredo, Joana Paredes, Carla Oliveira, Raquel Seruca.   

Abstract

E-cadherin plays a major role in cell-cell adhesion and inactivating germline mutations in its encoding gene predispose to hereditary diffuse gastric cancer. Evidence indicates that aside from its recognized role in early tumourigenesis, E-cadherin is also pivotal for tumour progression, including invasion and metastization. Herein, we discuss E-cadherin alterations found in a cancer context, associated cellular effects and signalling pathways, and we raise new key questions that will impact in the management of GC patients and families.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22841718     DOI: 10.1016/j.febslet.2012.07.045

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  33 in total

Review 1.  Role of gene polymorphisms in gastric cancer and its precursor lesions: current knowledge and perspectives in Latin American countries.

Authors:  Miguel Angel Chiurillo
Journal:  World J Gastroenterol       Date:  2014-04-28       Impact factor: 5.742

2.  Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR.

Authors:  Chiara Molinari; Raefa Abou Khouzam; Samanta Salvi; Tania Rossi; Guglielmina Nadia Ranzani; Daniele Calistri
Journal:  J Vis Exp       Date:  2018-02-05       Impact factor: 1.355

Review 3.  Pathogenetic mechanisms in gastric cancer.

Authors:  Jing Shi; Yi-Ping Qu; Peng Hou
Journal:  World J Gastroenterol       Date:  2014-10-14       Impact factor: 5.742

Review 4.  Perspectives on new biomarkers in gastric cancer: diagnostic and prognostic applications.

Authors:  Danilo do Rosário Pinheiro; Wallax Augusto Silva Ferreira; Mariceli Baia Leão Barros; Mariana Diniz Araújo; Symara Rodrigues-Antunes; Bárbara do Nascimento Borges
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

5.  Salvianolic acid B suppresses EMT and apoptosis to lessen drug resistance through AKT/mTOR in gastric cancer cells.

Authors:  Jie Wang; Yingze Ma; Min Guo; Haixia Yang; Xiaohui Guan
Journal:  Cytotechnology       Date:  2020-11-17       Impact factor: 2.058

6.  OTUB1 promotes metastasis and serves as a marker of poor prognosis in colorectal cancer.

Authors:  Yi Zhou; Jiangxue Wu; Xiang Fu; Wuying Du; Ling Zhou; Xiangqi Meng; Hongyan Yu; Jiaxin Lin; Wen Ye; Jiani Liu; Hui Peng; Ran-Yi Liu; Changchuan Pan; Wenlin Huang
Journal:  Mol Cancer       Date:  2014-11-28       Impact factor: 27.401

7.  Cadherin cytoplasmic domains inhibit the cell surface localization of endogenous E-cadherin, blocking desmosome and tight junction formation and inducing cell dissociation.

Authors:  Masayuki Ozawa; Wakako Kobayashi
Journal:  PLoS One       Date:  2014-08-14       Impact factor: 3.240

Review 8.  Helicobacter pylori CagA: From Pathogenic Mechanisms to Its Use as an Anti-Cancer Vaccine.

Authors:  Markus Stein; Paolo Ruggiero; Rino Rappuoli; Fabio Bagnoli
Journal:  Front Immunol       Date:  2013-10-15       Impact factor: 7.561

9.  PRL-3 and E-cadherin show mutual interactions and participate in lymph node metastasis formation in gastric cancer.

Authors:  Anna Pryczynicz; Katarzyna Guzińska-Ustymowicz; Katarzyna Niewiarowska; Dariusz Cepowicz; Andrzej Kemona
Journal:  Tumour Biol       Date:  2014-04-03

Review 10.  Gastric biomarkers: a global review.

Authors:  Nick Baniak; Jenna-Lynn Senger; Shahid Ahmed; S C Kanthan; Rani Kanthan
Journal:  World J Surg Oncol       Date:  2016-08-11       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.